Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.
AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.
In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.
AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.
The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.
For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.
AIM ImmunoTech Inc. (NYSE American: AIM) announced a live video webcast presentation by CEO Thomas K. Equels at the Virtual Investor 2023 Companies to Watch Event on January 18, 2023, at 11:00 AM ET. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its leading product, Ampligen®, is currently in clinical trials for pancreatic cancer and approved for treating chronic fatigue syndrome in Argentina. A replay of the webcast will be available on the company’s website for 90 days.
AIM ImmunoTech (NYSE American: AIM) has promoted Christopher McAleer, Ph.D., to Scientific Officer, reflecting his contributions since joining as Deputy Scientific Officer in June 2022. CEO Thomas K. Equels emphasized McAleer's vital role in advancing AIM's clinical development programs, particularly with the drug Ampligen. McAleer brings extensive experience from his previous role at Hesperos, where he significantly increased operational scale. AIM's Ampligen is currently in clinical trials for various cancers and approved for use in treating severe chronic fatigue syndrome.
AIM ImmunoTech (AIM) recently presented data at the British Society for Immunology Congress 2022 regarding the safety and efficacy of its intranasal treatment, Ampligen (rintatolimod). The study found that Ampligen was well-tolerated among healthy subjects, with no severe adverse events reported. The treatment potentially inhibits respiratory viruses, including SARS-CoV-2. Results indicated positive immune responses and support further development of Ampligen as a prophylactic option for respiratory infections.
AIM ImmunoTech Inc. (NYSE American: AIM) announced its abstract acceptance for poster presentation at the British Society for Immunology Congress 2022, scheduled for December 5-8, 2022, in Liverpool, UK. The poster, titled Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen, will be presented by Lisanne C.A. Smidt on December 7. Ampligen is currently in clinical trials for various conditions, including pancreatic cancer and COVID-19-related syndromes.
AIM ImmunoTech Inc. (NYSE American: AIM) reported its Q3 2022 financial results, noting a cash position of $36.7 million, sufficient for operations through 2023. The company is advancing multiple clinical studies for its lead product, Ampligen (rintatolimod), targeting various cancers and ailments, including COVID-19. Key updates include positive trial data for Ampligen in triple-negative breast cancer and FDA clearance for a Phase 2 study on post-COVID conditions. AIM is focused on reaching clinical milestones while managing operating losses, which increased to $6.4 million in Q3 2022.
AIM ImmunoTech Inc. (AIM) announced positive data from a Phase 1 study of Ampligen as part of a CKM regimen for early-stage triple negative breast cancer (TNBC). Results presented at the SITC 37th Annual Meeting show a pathologic complete response (pCR) rate of 56%, comparable to pembrolizumab-based treatments. The regimen, combining Ampligen, interferon-α2b, and celecoxib, was well tolerated with no dose-limiting toxicities. A Phase 2 study is planned to further evaluate Ampligen's efficacy as an alternative therapy.
AIM ImmunoTech Inc. announced plans to enhance its corporate governance by adding two directors with expertise in biotechnology commercialization and diversity. The board's Compensation Committee will consult an independent compensation expert to review executive pay, responding to shareholder feedback on past advisory votes.
In the previous year, AIM achieved significant clinical milestones, including positive outcomes in pancreatic cancer and other studies involving its lead product, Ampligen. These advancements aim to further align leadership with shareholder interests and boost AIM's value.
AIM ImmunoTech Inc. (AIM) announced the re-election of all three directors at its Annual Meeting of Shareholders. Directors Stewart Appelrouth, Thomas Equels, and William Mitchell received unanimous support. The company expressed gratitude towards shareholders and reaffirmed its commitment to advancing its lead drug, Ampligen, into oncology for long-term shareholder value. Ampligen is currently in clinical trials for various cancers and is approved in Argentina for chronic fatigue syndrome.
AIM ImmunoTech Inc. has received FDA Orphan Drug Designation for its immuno-modulator, Ampligen® (rintatolimod), targeting Ebola virus disease. This designation acknowledges Ampligen's potential in treating rare diseases, qualifying AIM for incentives like tax credits and possible market exclusivity. Although Ebola isn't a current primary focus, previous studies show Ampligen's efficacy against various viruses, including COVID-19. The firm is conducting ongoing clinical trials to further evaluate Ampligen's applications.
AIM ImmunoTech Inc. announced that the Delaware Court of Chancery denied Jonathan Jorgl's request for a preliminary injunction regarding his attempts to nominate directors to AIM's Board. The Court found Jorgl's nomination notice misleading and non-compliant with AIM's bylaws. Consequently, Jorgl's nominations will not be recognized in the upcoming Annual Meeting set for November 3, 2022. AIM urges shareholders to support the current Board, highlighting ongoing progress in clinical trials and the company’s efforts in oncology.
FAQ
What is the current stock price of AIM ImmunoTech (AIM)?
What is the market cap of AIM ImmunoTech (AIM)?
What is AIM ImmunoTech's main focus?
What are AIM ImmunoTech's key products?
What recent achievements has AIM ImmunoTech made?
Who are AIM ImmunoTech's notable partners?
What clinical trials is AIM ImmunoTech currently conducting?
How can investors access AIM ImmunoTech's financial reports?
How does AIM ImmunoTech engage with its stakeholders?
What is the significance of Ampligen in AIM ImmunoTech's portfolio?
Who leads AIM ImmunoTech?
Where can more information about AIM ImmunoTech be found?
